News

STAT Coverage of Rfk Jr. – Maha, Vaccines, Hhs, and More

Regulatory 72/100How we got 72/100Source tierEstablished referenceTier ceiling72/100Independent sourcesnot recordedPublished score72/100Scored at the ceiling for a established reference source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

An FDA advisory panel has voted to narrowly reject the compounding of tirzepatide while narrowly backing the compounding of semaglutide and another GLP-1 drug. This decision comes as the FDA faces political pressure from the Trump administration and Robert F. Kennedy Jr. to increase access to these weight-loss medications. The votes reflect a contentious debate between FDA staff warning about safety risks and peptide enthusiasts advocating for broader availability.

Related peptides

SemaglutideTirzepatideGLP-1Mounjaro
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.